Western Regional Ctr for Brain and Spine Surgery
Welcome,         Profile    Billing    Logout  
 11 Trials 
42 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Smith, William B
CHALLENGE-MIG, NCT05127486: A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine

Checkmark Enrollment initiated in combination with Emgality for episodic migraine
Nov 2021 - Nov 2021: Enrollment initiated in combination with Emgality for episodic migraine
Completed
4
580
US
Galcanezumab, LY2951742, Rimegepant, Placebo
Eli Lilly and Company
Migraine, Episodic Migraine
05/23
05/23
NCT05518123 / 2022-001176-34: Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications

Recruiting
4
600
Europe, Canada, US, RoW
Rimegepant, Placebo
Pfizer, Pfizer
Migraine
02/25
08/25
NCT04240626: Multimodal Analgesia Effect on Post Surgical Patient

Recruiting
4
60
US
Neurontin, Gabapentin, Dilaudid Injectable Product, Hydromorphone, Marcaine Injectable Product, Oxycodone Hydrochloride, Hycet 7.5Mg-325Mg/15Ml Solution, Hydrocodone, Zofran Injection, Odanesetron, Scopolamine patch, Scopolamine, Ativan, Flexeril Oral Product, Cyclobenziparin, Tylenol Suspension, Acetaminophen
University of California, Davis
Obesity, Morbid, Surgery, Bariatric Surgery Candidate
12/24
12/25
NCT05590403 / 2022-001981-36: A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above

Completed
3
1544
Europe, Canada, Japan, US, RoW
RSVPreF3 OA investigational vaccine, Placebo
GlaxoSmithKline
Respiratory Syncytial Virus Infections
03/23
04/24
NCT06153693: Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

Active, not recruiting
3
1083
Europe, Canada, US, RoW
Placebo, lorundrostat Dose 1, lorundrostat Dose 2
Mineralys Therapeutics Inc.
Hypertension
12/24
02/25
NCT06015282: The Celljuvant Study: a Phase 3 Immunogenicity and Safety Study of AQIVc Vaccine in Adults Aged 50 Years and Older

Active, not recruiting
3
7741
Europe, Canada, US, RoW
Investigational aQIVc, licensed QIV1, licensed QIV2
Seqirus
Influenza, Human
03/24
01/25
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
NCT06389487: A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above

Active, not recruiting
3
1457
Europe, Canada, Japan, US, RoW
RSVPreF3 OA investigational vaccine
GlaxoSmithKline
Respiratory Syncytial Virus Infections
07/24
04/25
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
ORCA-OL, NCT06435221: Safety Study of Cytisinicline in Adult Combustible And/or E-cigarette Smokers

Active, not recruiting
3
650
US
Cytisinicline, Cytisine
Achieve Life Sciences
Smoking Cessation, Vaping Cessation
12/25
12/25
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
ATTAIN-2, NCT05872620: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

Active, not recruiting
3
1500
Europe, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight, Type 2 Diabetes
08/25
08/25
NCT05968430: Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects with Hypertension

Enrolling by invitation
3
1400
Europe, Canada, US, RoW
lorundrostat, Placebo
Mineralys Therapeutics Inc.
Hypertension
12/25
12/26
GUIDANCE, NCT05050084: Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score

Recruiting
3
2050
Canada, US
Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Buserelin, 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig), BSRL, Busereline, Etilamide, HOE 766, ICI 123215, S74-6766, Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, Nubeqa, ODM 201, ODM-201, Degarelix, FE200486, Firmagon, Flutamide, 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, Sch 13521, Tafenil, Tecnoflut, Testotard, Goserelin, ICI-118630, Histrelin, Leuprolide, Leuprorelin, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Relugolix, N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea, Orgovyx, TAK 385, TAK-385, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Detryptoreline
NRG Oncology, National Cancer Institute (NCI)
Prostate Adenocarcinoma
04/32
04/37
PREDICT-RT, NCT04513717: Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The Trial

Recruiting
3
2478
Canada, US
Apalutamide, ARN 509, ARN-509, ARN509, Erleada, JNJ 56021927, JNJ-56021927, Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Buserelin, 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig), BSRL, Busereline, Etilamide, HOE 766, ICI 123215, S74-6766, Degarelix, FE200486, Firmagon, Flutamide, 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, Sch 13521, Tafenil, Tecnoflut, Testotard, Goserelin, ICI-118630, Histrelin, Leuprolide, Leuprorelin, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Detryptoreline
NRG Oncology, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Bone, Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
12/33
12/33
NCT05975060: A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.

Completed
2/3
660
US
XBB.1.5 Vaccine (Booster), Omicron sub variant XBB.1.5 vaccine( booster) SARS-CoV-2 rS /Matrix-M Adjuvant, XBB.1.5 Vaccine (single dose), Omicron sub variant XBB.1.5 vaccine(single dose) SARS-CoV-2 rS /Matrix-M Adjuvant
Novavax
COVID-19
11/23
05/24
NCT04809376: Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA Pain

Active, not recruiting
2/3
602
US, RoW
Pentosan Polysulfate Sodium twice weekly, PPS twice weekly, Placebo (Sodium Chloride Injection, 0.9%), Placebo, Pentosan Polysulfate Sodium Fixed Dose, Fixed Dose, Pentosan Polysulfate Sodium once weekly, PPS once weekly
Paradigm Biopharmaceuticals USA (INC)
Osteoarthritis, Knee
10/24
01/25
NCT05067933: A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine

Completed
2
66
US
VXA-CoV2-1.1-S, Oral Tableted Ad5 COVID-19 Vaccine, Placebo Tablets
Vaxart
COVID-19
05/22
08/23
NCT06431607: A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults

Active, not recruiting
2
838
US
Flu Seasonal mRNA Formulation 1, GSK4382276A, Flu Seasonal mRNA Formulation 2, Flu Seasonal mRNA Formulation 3, Flu Seasonal mRNA Formulation 4, Flu Seasonal mRNA Formulation 5, Flu Seasonal mRNA Formulation 6, Flu Seasonal mRNA Formulation 7, Flu Seasonal mRNA Formulation 8, Active Comparator 1, Active Comparator 2, Flu Seasonal mRNA Formulation 9, Flu Seasonal mRNA Formulation 10, Active Comparator 3, Active Comparator 4
GlaxoSmithKline
Influenza, Human
11/24
06/25
ZUPREME-1, NCT06662539: Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities

Recruiting
2
480
Europe, US
Petrelintide, ZP8396, Placebo
Zealand Pharma, Parexel
Obesity
11/25
04/26
NCT06151288: Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults

Completed
1/2
1015
US
31 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine, PCV20, Prevnar 20™
Vaxcyte, Inc.
Pneumococcal Vaccines
07/24
07/24
NCT05975840: Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults

Completed
1/2
518
US
FLU Q-PAN H5N8 Formulation 1, AS03B, AS03A, FLU Q-PAN H5N8 Formulation 2
GlaxoSmithKline
Influenza, Human
12/23
05/24
NCT05823974: A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults

Active, not recruiting
1/2
1256
Europe, Canada, US, RoW
Flu mRNA, GSK4382276A, Control 1, Control 2
GlaxoSmithKline, CureVac
Influenza, Human
07/24
08/24
NCT06680375: A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults

Active, not recruiting
1/2
780
US
Flu Seasonal /SARS-CoV-2 mRNA Dose 1, Flu Seasonal /SARS-CoV-2 mRNA Dose 2, Flu Seasonal mRNA, SARS-CoV-2 mRNA Dose 1, SARS-CoV-2 mRNA Dose 2, Licensed Flu Seasonal, Licensed COVID-19 mRNA, Placebo, Phase 2 selected Investigational Flu Seasonal/SARS-CoV-2 mRNA, Phase 2 selected SARS-CoV-2 mRNA
GlaxoSmithKline
COVID-19
05/25
11/25
NCT05961397: Phase 1 PK Study to Evaluate the PK of CIN-107 in Subjects With Hepatic Impairment

Completed
1
20
US
baxdrostat, CIN-107
AstraZeneca
Hypertension
04/22
04/22
Study 1100, NCT03589339: NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy

Recruiting
1
145
US
NBTXR3, SABR, Stereotaxic Ablative Radiotherapy, Stereotaxic Body Radiation Therapy, Nivolumab, Opdivo, Pembrolizumab, Keytruda
Nanobiotix
Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour, Metastasis from Malignant Tumor of Liver, Squamous Cell Carcinoma of Head and Neck, Metastasis from Malignant Tumor of Cervix, Metastatic Renal Cell Carcinoma, Metastasis from Malignant Melanoma of Skin (disorder), Metastatic Triple-Negative Breast Carcinoma, Metastatic NSCLC, Metastasis from Malignant Tumor of Bladder (Disorder)
04/27
05/28
NCT03896750: Single-Dose Study to Evaluate the PKs of Pretomanid in Participants With Renal Impairment Compared to Participants With Normal Renal Function

Recruiting
1
36
US
PA-824
National Institute of Allergy and Infectious Diseases (NIAID)
Renal Impairment, Tuberculosis
01/25
07/25
NCT05711381: Phase 1 PK Study to Assess Safety, PK, Tolerability of HM15912 in Subjects With Renal Impairment and Normal Renal Function

Completed
1
16
US
HM15912
Hanmi Pharmaceutical Company Limited
Renal Impairment
08/23
08/23
NCT05194358: Study of SIAN Nasal Spray in Healthy Adults

Completed
1
47
US
Stabilized Isoamyl Nitrite (SIAN)
Emergent BioSolutions, Biomedical Advanced Research and Development Authority
Cyanide Poisoning
09/23
10/23
NCT05936138: A Study of LY3502970 in Participants With Normal and Impaired Renal Function

Completed
1
24
US
LY3502970
Eli Lilly and Company
Renal Insufficiency, Healthy
04/24
04/24
NCT05778864: A Study of LY3473329 in Participants With Impaired and Normal Renal Function

Completed
1
47
US
LY3473329
Eli Lilly and Company
Renal Insufficiency
09/24
09/24
NCT05967195: Trial to Increase FEP Attendance

Recruiting
1
145
US
Financial Incentive and Text-Messages
University of Pennsylvania, Penn Innovation in Suicide Prevention for Implementation Research (INSPIRE) Center
First-Episode Psychosis
09/25
09/25
NCT06179290: Changes in Biomarker of Exposure in Adults Who Smoke Cigarettes Switching From Cigarettes to Heated Tobacco Products

Active, not recruiting
N/A
300
US
Ploom HTP Menthol HTS; MX3 (681), Ploom HTP Tobacco HTS; R8 (120), Smoking Abstinence (menthol), Smoking Abstinence (non-menthol)
Altria Client Services LLC, Celerion
Tobacco Use
05/24
03/25
NCT06356610: Pharmacokinetic and Subjective Effects of Heated Tobacco Products

Active, not recruiting
N/A
60
US
Test Product A, Ploom® 3.1 HTP - Menthol HTS; MX3 (681), Test Product B, Ploom® 3.1 HTP - Menthol HTS; MX5 (706), Test Product C, Ploom® 3.1 HTP - Tobacco HTS; R8 (120), Test Product D, Ploom® 3.1 HTP - Tobacco HTS; RX4 (953), Reference Product E, Nicorette® 4 mg Mint Nicotine Gum, Reference Product F, Combustible Cigarette (menthol or nonmenthol), participant's usual brand
Altria Client Services LLC, Celerion
Tobacco Use
04/24
06/25
NCT05765266: ACP Max™ PRP System for Knee Osteoarthritis: A Feasibility Trial

Recruiting
N/A
45
US
ACP Max™, Depo-Medrol®, methylprednisolone acetate)
Arthrex, Inc.
Knee Osteoarthritis
05/25
05/26
NCT06303115: CSD231005 Nicotine Pouch Biomarkers of Exposure

Recruiting
N/A
200
US
Nicotine Pouch P1312914, 4 mg nicotine, Nicotine Pouch P1312915, 8 mg nicotine, Nicotine Pouch P1013215, 8 mg nicotine, Nicotine Pouch P1013218, 10 mg nicotine, Nicotine Pouch P1012919, 12 mg nicotine, Smoking Abstinence, Continued UB cigarette smoking
RAI Services Company
Tobacco Use, Smoking
12/24
01/25
NCT01034969: Firazyr® Patient Registry (Icatibant Outcome Survey - IOS)

Completed
N/A
1761
Europe, RoW
Shire, Takeda Development Center Americas, Inc.
Hereditary Angioedema (HAE)
05/24
05/24
NCT04427384: Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)

Recruiting
N/A
600
US
GammaTile
GT Medical Technologies, Inc.
Brain Tumor, Recurrent, Brain Tumor, Brain Tumor, Primary, Brain Tumor - Metastatic, Brain Tumor, Adult: Glioblastoma, Brain Tumor, Adult Meningioma
10/28
12/28
NCT02024542: Metabolic Responses to Bariatric Surgery

Recruiting
N/A
500
US
Surgery
University of California, Davis
Morbid Obesity
04/35
04/35
Gupta, Karishma
NCT04452955: A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors

Active, not recruiting
2
51
US
PRL3-zumab
Intra-IMMUSG Pte Ltd, Parexel
Solid Tumor
12/24
06/25
BA3011-002, NCT04681131 / 2022-000135-23: CAB-AXL-ADC Safety and Efficacy Study in Adults with NSCLC

Active, not recruiting
2
240
Europe, US, RoW
CAB-AXL-ADC, BA3011, PD-1 inhibitor
BioAtla, Inc., BioAtla Inc.
Non-Small-Cell Lung Cancer
08/25
08/25
BA3021-001, NCT03504488 / 2022-000137-17: CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

Completed
1/2
132
Europe, US, RoW
CAB-ROR2-ADC, BA3021, PD-1 inhibitor
BioAtla, Inc., BioAtla Inc.
Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer
12/24
12/24

Download Options